EMERGENT STRATEGIES

Lobbying for GENBIOPRO, INC. · Generic Pharmaceutical Manufacturer

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$35,000.00

What the client paid this registrant for the period.

Client based in

Nevada

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 3

Pharmacy

FDA Approval of generic mifepristone and relate Risk Evaluation Mitigation Strategies (REMS)

Veterans

VA rule making on providing abortion services to veterans

Health Issues

Issues related to medication abortion; Issues related to abortion access

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.